Application of IVIVCs in Formulation Development Douglas F Smith
|
|
- Ashley White
- 6 years ago
- Views:
Transcription
1 Application of IVIVCs in Formulation Development Douglas F Smith PQRI Workshop on Application of IVIVC in Formulation Development September 5-6, 2012 Bethesda, Maryland
2 In Vitro/In Vivo Correlations - Goals Establish a correlation between in vitro drug dissolution and in vivo drug absorption Develop a model that can accurately predict bioavailability characteristics for a drug product based on dissolution profile characteristics
3 Applications of IVIVC Understanding key formulation variable(s) Biowaivers for changes in drug product Lower strengths New strengths Changes in components and/or composition (within SUPAC guidelines) - Release rate controlling - Non-release rate controlling Changes in manufacturing site, process and/or equipment (within SUPAC guidelines) Setting dissolution specifications Justification of limits other than +/-10%
4 Development of IVIVC In vitro release (Dissolution at multiple ph and agitations) Administration to healthy volunteers (Crossover design) Design of MR Formulations IVIVC Deconvolution (Absorption)
5 Practical Application: In Vivo and In Vitro Data Required In Vivo Data Bioavailability Studies At least 2 test formulations with different release rates (3 or more recommended) Solution, immediate release, or IV reference (unit impulse response) Crossover studies in fasted subjects Parallel studies acceptable (common treatment across studies) In Vitro Data Dissolution Studies Test formulations should exhibit at least 10% difference in dissolution USP apparatus I 100 rpm) or II 50 rpm) preferred Adjust dissolution conditions to fit in vivo data/obtain proper discrimination If dissolution is faster or slower than in vivo absorption, adjust the time scale
6 Case Study 1 BCS Class III Drug Fraction absorbed approximately 80% Reformulation of a currently marketed modified release formulation IVIVC desired to support site change for manufacture of reformulated drug product
7 Plasma Concentrations Following Oral Administration 5 4 Formulation B (Fast Release) Formulation A (Slow Release) Formulation C (Medium Release) Market Product Reference IR Reference [Drug] (ng/ml) Time (Hours)
8 Dissolution and Absorption Profiles Water as Dissolution Medium Drug Dissolution Drug Absorption Cumulative Percent Label Claim Dissolved Slow Release Medium Release Fast Release Cumulative Relative Percent Absorbed Slow Release Medium Release Fast Release Time (Hours) Time (Hours)
9 IVIVC Model Water as Dissolution Medium Cumulative Percent Absorbed Slow Release Formulation Medium Release Formulation Fast Release Formulation Slow and Fast IVIVC R 2 = Cumulative Percent Dissolved
10 IVIVC Validation Internal Validation Predict plasma concentration-time profiles, C max and AUC values using in vitro dissolution data for the formulations that were used to develop the IVIVC Average absolute percent prediction error (%PE) of 10% or less for C max and AUC and no individual %PE of individual formulation more than 15% validates IVIVC External Validation Predict plasma concentration-time profiles, C max and AUC values using in vitro dissolution data for a formulation that was not used in the development of IVIVC %PE of 10% or less for C max and AUC validates IVIVC Proof of external validation provides greater confidence in IVIVC than internal validation
11 Level A IVIVC Validation Water as Dissolution Medium Internal Predictability Formula Obs AUC Pred AUC %PE Obs C max Pred C max %PE Slow Release Fast Release Average %PE 4.84 Average %PE 13.7 External Predictability Formula Obs AUC Pred AUC %PE Obs C max Pred C max %PE Medium Release AUC units: ng-hr/ml, C max units: ng/ml
12 Dissolution and Absorption Profiles - Acetate Buffer as Dissolution Medium Drug Dissolution Drug Absorption Cumulative Percent Label Claim Dissolved Slow Release Medium Release Fast Release Cumulative Relative Percent Absorbed Slow Release Medium Release Fast Release Time (Hours) Time (Hours)
13 IVIVC Model Acetate Buffer as Dissolution Medium Cumulative Percent Absorbed Slow Release Formulation Medium Release Formulation Fast Release Formulation Slow and Fast IVIVC R 2 = Cumulative Percent Dissolved
14 Level A IVIVC Validation Acetate Buffer as Dissolution Medium Internal Predictability Formula Obs AUC Pred AUC %PE Obs C max Pred C max %PE Slow Release Fast Release Average %PE 4.69 Average %PE 5.93 External Predictability Formula Obs AUC Pred AUC %PE Obs C max Pred C max %PE Medium Release AUC units: ng-hr/ml, C max units: ng/ml
15 Dissolution of Target Formulation Acetate Buffer as Dissolution Medium 100 Cumulative Percent Label Claim Dissolved Medium Release Formulation Target Release Formulation Candidate Target Release Formulation Time (Hours)
16 Plasma Concentrations Following Oral Tablet Administration 5 4 Observed Levels for Target Formulation Observed Levels for Market Product Reference [Drug] (ng/ml) Time (Hours)
17 Level A IVIVC Validation Acetate Buffer as Dissolution Medium Internal Predictability Formula Obs AUC Pred AUC %PE Obs C max Pred C max %PE Slow Release Fast Release Average %PE 4.69 Average %PE 5.93 External Predictability Formula Obs AUC Pred AUC %PE Obs C max Pred C max %PE Medium Release Target Release AUC units: ng-hr/ml, C max units: ng/ml
18 Setting of Dissolution Specifications Dissolution at Release Dissolution at Release (%) and After 3 Months (%) Time (Hr) Mean -10% +10% -3 SD +3 SD Mean - 3SD +3 SD Simulated Bioavailability Parameters Parameter Mean -10% +10% -3 SD +3 SD Mean - 3SD +3 SD AUC % Diff from Mean % Diff Low to High Cmax % Diff from Mean % Diff Low to High
19 Case Study 2 BCS Class II Drug Highly variable pharmacokinetics AUC and Cmax dependent upon input rate Reformulation of generic formulation to IR reference drug products at three dose levels Controlled release required to achieve bioequivalence to reference drug product IVIVC desired to support change in tablet coating and change in site of manufacture
20 Mean Plasma Concentration-Time Profiles Following Administration of Low Dose Reformulation Candidates 1400 [MPA] (pg/ml) % Polymer 4.5% Polymer 5.25% Polymer 6.25% Polymer 6.5% Polymer 7.0% Polymer 0% Polymer Reference Time (Hours)
21 Dissolution of Low Dose Reformulation Candidates by QC Release Method (USP Monograph) 100 Cumulative Percent Label Claim Dissolved % Polymer 5.25% Polymer 6.25% Polymer 6.5% Polymer 7.0% Polymer 8.0% Polymer Time (Minutes)
22 % Polymer Prediction Model to Achieve Bioequivalence for Low Dose Formulations 2.5 % Polymer vs C max Ratio R 2 = C max and AUC Geometric Mean Ratios Maximum GMR for C max % Polymer vs AUC Ratio R 2 = % Polymer = 6.40 Minimum GMR for AUC % Polymer = % Polymer
23 Mean Dissolution and Absorption Profiles of Drug From Low Dose Formulation Candidates Dissolution Absorption Cumulative Percent Label Claim Dissolved % Polymer 5.25% Polymer 4.5% Polymer 6.25% Polymer 6.5% Polymer 7% Polymer Cumulative Relative Percent Absorbed % Polymer 5.25% Polymer 4.5% Polymer 6.25% Polymer 6.5% Polymer 7% Polymer Time (Hours) Time (Hours)
24 Absorption Versus Dissolution Relationship for Drug From Low Dose Reformulation Candidates % Polymer 5.25% Polymer 6.25%% Polymer 6.5% Polymer 7% Polymer 8% Polymer IVIVC Model R 2 = Absorption Dissolution
25 Internal and External Predictability Measures of the Level A IVIVC for Drug from Low Dose Formulation Candidates Internal Predictability Formula Obs AUC Pred AUC %PE Obs C max Pred C max %PE 8.0% Polymer 7.0% Polymer 4.5% Polymer 5.25% Polymer 6.25% Polymer 6.5% Polymer Average % PE 4.06 Average % PE 5.36 External Predictability AUC units: pg-hr/ml, C max units: pg/ml
26 Dissolution Specifications For Low Dose Formuation Dissolution IVIVC Based Absence of IVIVC Time (Hr) Mean Lower Upper Lower Upper NLT 73 NLT 72 Parameter Simulated Bioavailability Parameters AUC % Diff from Mean -- 12% 10% 14% 11% % Diff Lower to Upper -- 20% 22% Cmax % Diff from Mean -- 8% 12% 9% 13% % Diff Lower to Upper -- 18% 20%
27 Dissolution Specifications For Low Dose Formuation Dissolution FDA Proposed Wyeth Proposed Time (Hr) Mean Lower Upper Lower Upper NLT 80 NLT 73 Parameter Simulated Bioavailability Parameters AUC % Diff from Mean -- 10% 10% 12% 8% % Diff Lower to Upper -- 18% 18% Cmax % Diff from Mean -- 6% 14% 3% 19% % Diff Lower to Upper -- 17% 19%
28 Controlled Release Formulation IR or MR? PK and PD profile is that of an IR drug product Clinical safety and efficacy profile is that of an IR drug product Product does not meet requirements of MR dosage formulation No reduction in dosing frequency No reduction in plasma concentration fluctuations No modified release characteristics exhibited in plasma concentration-time profile Are changes to formulation subject to SUPAC-IR guidance or SUPAC-MR guidance?
29 % Polymer Prediction Model to Achieve Bioequivalence for Medium Dose Formulations 2.0 C max Ratios BA Study 1.8 AUC Ratios BA Study C max Ratios BE Study AUC Ratios BE Study C max and AUC Geometric Mean Ratios Maximum GMR for C max % Polymer = Minimum GMR for AUC % Polymer = % Polymer
30 % Polymer Prediction Model to Achieve Bioequivalence for High Dose Formulations 1.8 C max and AUC Geometric Mean Ratios % Polymer = 2.89 % Polymer = 3.95 C max Ratios BA Study AUC Ratios BA Study C max Ratios BE Study AUC Ratios BE Study Maximum GMR for C max Minimum GMR for AUC % Polymer
31 Case Study 3 BCS Class I Drug Development of MR dosage for an existing IR market product Initial IVIVC developed with data from slow, medium and fast release formulations Small scale batches Lowest strength to be marketed IVIVC desired to support change in process parameters and change in site of manufacture
32 In vitro release and in vivo absorption profiles from 75 mg Formulations Dissolution Absorption Cumulative Percent Label Claim Dissolved Slow Release Medium Release Fast Release Dissolution Conditions: - USP I (baskets) rpm - 0.9L Water - 37 o C Cumulative Percent Absorbed Slow Release Medium Release Fast Release Time (Hours) Time (Hours)
33 In Vitro / In Vivo Relationship for 75mg Capsules 100 Slow Release Medium Release Fast Release Linear Regression R 2 = Cumulative Percent Absorbed Cumulative Percent Dissolved
34 Internal and External Predictability Measures of the Level A IVIVC Internal Predictability Formula Obs AUC Pred AUC %PE Obs C max Pred C max %PE Slow Release Medium Release Fast Release Average % PE 4.74 Average % PE 12.5 External Predictability 2x75mg x150mg AUC units: mcg-hr/ml, C max units: mcg/ml
35 Demonstration of in vitro release independence of dissolution test conditions Dissolution tests for 75mg and 150mg formulations USP I (baskets) and USP II (paddles) at 50, 75 and 100 rpm Dissolution media of water, SGF (without enzymes) and SIF (without enzymes All dissolution profiles similar to reference profile (USP I, 100 rpm, water) - f 2 > 65 Dissolution tests for 225mg formulations USP I (baskets) at 100 rpm Dissolution media of water, SGF (without enzymes), buffers at ph 4.5, 6.8 and 7.4 All dissolution profiles similar to reference profile (USP I, 100 rpm, water) - f 2 > 78
36 In Vitro / In Vivo Relationship for 75mg and 150mg Formulations Study 1 75 mg US Mfg Study 1 75 mg PR Mfg Study mg PR Mfg Study 2 75 mg US Mfg Study mg PR Mfg IVIVC Model R 2 = Cumulative Percent Absorbed Cumulative Percent Dissolved
37 Internal Predictability Measures of the Level A IVIVC Internal Predictability Formula Obs AUC Pred AUC %PE Obs C max Pred C max %PE 2x75mg Study 2 1x150mg Study 2 2x75mg Study 1 1x150mg Study 1 2x75mg Study Average % PE 4.16 Average % PE 7.61 AUC units: mcg-hr/ml, C max units: mcg/ml
38 Case Study 4 BCS Class III Drug Fraction absorbed approximately 80% Development of MR dosage for which no IR market product Multiple strengths developed to achieve same in vitro dissolution release profile 50mg 70% HPMC 75mg 57% HPMC 100mg 50% HPMC 200mg 30% HPMC IVIVC desired to support development of other strengths
39 MR Tablet Dissolution Profiles in 0.9% NaCl 100 Cumulative Percent Label Claim Dissolved mg 100 mg 200 mg Time (Hours)
40 50 mg MR Tablet Dissolution Profiles in Alternate Media 100 Cumulative Percent Label Claim Dissolved % NaCl - Reference Media Water, f 2 = N HCl (ph 1.0), f 2 = N HCl / 0.2M Phosphate (Two-Stage), f 2 = M Acetate (ph 4.5), f 2 = M Phosphate (ph 6.8), f 2 = Time (Hours)
41 200 mg MR Tablet Dissolution Profiles in Alternate Media 100 Cumulative Percent Label Claim Dissolved % NaCl - Reference Media Water, f 2 = N HCl (ph 1.0), f 2 = N HCl / 0.2M Phosphate (Two-Stage), f 2 = M Acetate (ph 4.5), f 2 = M Phosphate (ph 6.8), f 2 = Time (Hours)
42 MR Tablets Absorption Profiles 100 Cumulative Percent Label Claim Absorbed mg 100 mg 200 mg Time (Hours)
43 In Vitro / In Vivo Relationship for MR Tablets Cumulative Percent Absorbed mg 100 mg 200 mg Linear Regression R 2 = Cumulative Percent Dissolved
44 Validation of Level A IVIVC for MR Tablets Internal Predictability Formula Obs AUC Pred AUC %PE Obs C max Pred C max %PE 2x50 mg x100 mg x200 mg Average % PE 8.88 Average % PE 2.05 External Predictability 2x75 mg AUC units: mcg-hr/ml, C max units: mcg/ml
45 Approaches to a Level A IVIVC Traditional Approach Non-traditional Approach % absorbed Vs % dissolved mg absorbed Vs mg dissolved One strength Multiple strengths Multiple formulations with different levels of rate-controlling parameter Multiple formulations with different levels of rate-controlling parameter Differences among formulations in both % and mg released profiles Differences among formulations only in mg released profiles Point to point relationship between in vitro dissolution (%) and in vivo dissolution (%) Point to point relationship between in vitro dissolution (mg) and in vivo dissolution (mg)
46 FDA Guidance on Development, Evaluation and Application of IVIVCs Traditional Approach Level A Correlation is.... comparison of fraction of drug absorbed to the fraction of drug dissolved release rates, as measured by percent dissolved, for each formulation studied, should differ adequately (e.g., 10%) most commonly seen processes Non-traditional Approach Alternative approaches to developing Level A IVIVCs are possible Whatever the method used to establish a Level A IVIVC, the model should predict the entire in vivo time course from the in vitro data. In this context, the model refers to the relationship between in vitro dissolution of an ER dosage form and an in vivo response such as plasma drug concentration or amount of drug absorbed Release rate: Amount of drug released per unit time as defined by in vitro or in vivo testing
47 MR Tablet Dissolution Profiles (Cumulative % Dissolved in 0.9% NaCl) 100 Cumulative Percent Label Claim Dissolved mg 100 mg 200 mg Time (Hours)
48 MR Tablet Dissolution Profiles (Cumulative mg Dissolved in 0.9% NaCl) mg (70% HPMC) 100 mg (50% HPMC) 200 mg (30% HPMC) Cumulative mg Label Claim Dissolved Time (Hours)
49 MR Tablets Absorption Profiles (Cumulative % Absorbed) 100 Cumulative Percent Label Claim Absorbed mg 100 mg 200 mg Time (Hours)
50 MR Tablet Absorption Profiles (Cumulative mg Absorbed) mg (70% HPMC) 100 mg (50% HPMC) 200 mg (30% HPMC) Cumulative mg Label Claim Absorbed Time (Hours)
51 In Vitro / In Vivo Relationship for MR Tablets mg 100 mg 200 mg Linear Regression R 2 = Cumulative mg Absorbed Cumulative mg Dissolved
52 Validation of Level A IVIVC for MR Tablets Internal Predictability Formula Obs AUC Pred AUC %PE Obs C max Pred C max %PE 2x50 mg x100 mg x200 mg Average % PE 8.19 Average % PE 2.35 External Predictability 2x75 mg AUC units: mcg-hr/ml, C max units: mcg/ml
53 INTERNAL AND EXTERNAL PREDICTABILITY MEASURES OF LEVEL A IVIVC FOR 200 mg MR TABLETS Batch 15% HPMC Roller Compact MFG Site A 30% HPMC Roller Compact MFG Site A Batch 30% HPMC Wet Granulation MFG Site B Observed AUC Predicted AUC Intern al Predictability Absolute % PE Observed Cmax Predicted Cmax Absolute % PE Observed AUC Average % PE 2.57 Averag e % PE 3.51 Predicted AUC External Predictability Absolute % PE Observed Cmax Predicted Cmax Absolute % PE AUC units: ng hr/ml; Cmax units: ng/ml
54 Evaluation of Dissolution Specifications Time Point Statistical Limits 95% Chance of Passing L1 Statistical Limits 99% Chance of Passing L1 Limits Based on IVIVC 2 hours NMT 33% NMT 34% 17 37% 4 hours 33 50% 32 51% 32 52% 8 hours 50 73% 50 75% 52 72% 12 hours 63 95% 63 95% 69 89% 24 hours NLT 83% NLT 82% NLT 87%
55 Case Study 5 BCS Class I Drug Development of IVIVC for Marketed MR Product Change in process Multiple strengths manufactured and exhibit same in vitro dissolution release profile Retrospective analysis of data available from 7 BA studies Drug has significant first-pass metabolism Data from intubation study indicated increase in systemic availability in distal GI Correlation model developed using dissolution data directly as input First derivative of Weibull Function
56 Model Parameters of Dissolution Data
57 Model of Fraction of Drug Absorbed
58 Validation of the Model
59 Validation of the Model
60 Dissolution of Drug
61 Conclusions-Benefits of IVIVC Provides framework for formulation development Promotes prioritization of formulation efforts toward compounds with bioavailability problems and improves communication across disciplines Places development of biorelevant dissolution method formally into development process Defines manufacturing parameters at an early stage in the development process and facilitates early transfer of formulation to manufacturing site Reduces the risk of requiring Phase III to market BE studies
62 IVIVCs Lessons Learned FDA guidance is just that, not a regulation or requirement, but it is in the best interest of sponsor to evaluate feasibility Terminology in the guidance indicates sponsors are allowed some flexibility in developing IVIVCs Collaboration among various functional groups a necessity (formulations, analytical, clinical, regulatory, biopharmaceutics) Timing Developing IVIVCs is not a science, it is an art.
63 Acknowledgements Pharmaceutical Sciences Robin Enever Technical Services Stephen White Mike Dey John Pendregast Richard DeNeale Biopharmaceutics Sridhar Duvvuri Clinical Phil Mayer William McKeand Formulations Alice Nichols Ron Warner Steven Troy John Michelucci Deborah Sherman Regulatory David Korman John Clark James Murphy Shaleish Singh Simon Golec Chris Diorio Beth Kendsersky Ian Armstrong Chris Le Analytical Services Andy Beath Lusan Yao Patricia Mann Brian Spencer Marijo Weinzierl Quality Operations Joe DeVito David Sheats Deborah Parker Consultants Lewis Leeson Scott Stevens William Barr William Jock Mario Gonzalez
Establishing Prospective IVIVC for Generic Pharmaceuticals: Methodologies Assessment
Send Orders for Reprints to reprints@benthamscience.net The Open Drug Delivery Journal, 2014, 5, 1-7 1 Open Access Establishing Prospective IVIVC for Generic Pharmaceuticals: Methodologies Assessment Sumon
More informationBCS: Dissolution Testing as a Surrogate for BE Studies
BCS: Dissolution Testing as a Surrogate for BE Studies Dirk M Barends National Institute of Public Health and the Environment The Netherlands APV / IKEV Seminar on Bioavailability and Bioequivalence, Istanbul,
More informationEffect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs
Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs James E. Polli jpolli@rx.umaryland.edu April 26, 2016 Topics BCS Class 3 excipient study
More informationRevised European Guideline on PK and Clinical Evaluation of Modified Release Dosage Forms
1st MENA Regulatory Conference on Bioequivalence, Biowaivers, Bioanalysis and Dissolution Jordan September 23 24, 2013 Revised European Guideline on PK and Clinical Evaluation of Modified Release Dosage
More informationBiowaiver and Dissolution Profile Comparison
Biowaiver and Dissolution Profile Comparison Triporn Wattananat Bureau of Drug and Narcotic Department of Medical Sciences June 14, 2011 Biowaiver Outline: 1. Introduction 2. Biopharmaceutics Classification
More informationREGULATORY PERSPECTIVE. Dr. Raghunandan H V Associate Professor JSSCP, JSSU, Mysore
1 REGULATORY PERSPECTIVE Dr. Raghunandan H V Associate Professor JSSCP, JSSU, Mysore Contents 2 1. Role of Dissolution Testing in Generic Drug Approval 2. Dissolution Testing Recommendation for Solid Oral
More information7. SUMMARY, CONCLUSION AND RECOMMENDATIONS
211 7. SUMMARY, CONCLUSION AND RECOMMENDATIONS Drug absorption from the gastro intestinal tract can be limited by various factors with the most common one being poor aqueous solubility and poor permeability
More informationIn vitro In vivo correlation of sustained release capsules of Metoprolol
In vitro In vivo correlation of sustained release capsules of Metoprolol K.Kannan*, R.Manavalan, P.K.Karar Department of Pharmacy, Annamalai University, Annamalai Nagar-608002, TamilNadu, India. ABSTRACT
More informationHelmut Schütz. Training on Bioequivalence Kaunas, 5 6 December
Dissolution / Biowaivers / IVIVC Helmut Schütz Training on Bioequivalence Kaunas, 5 6 December 2017 1 Human Guineapigs I BE as a surrogate for clinical efficacy / safety ( essential similarity ) We want
More informationBiowaiver Study on Prednisolone Tablets 5 mg in Three Different Brands. Marketed in Sudan. Safaa Mohamed *, Tilal Elsaman
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2017, 9 [4]:8-114 [http://scholarsresearchlibrary.com/archive.html] ISSN 0975-5071 USA CODEN: DPLEB4
More informationSPS Pharma: Who we are?
Applications in area of drug release using the flow through cell Society of Pharmaceutical Dissolution Science 26-27th July 2016 Ahmedabad (India) Samir Haddouchi samir.haddouchi@sps-pharma.com www.sps-pharma.com
More informationGuideline for Bioequivalence Studies of Generic Products
English translation of Attachment 1 of Division-tification 0229. 10 of the Pharmaceutical and Food Safety Bureau, dated February 29, 2012 Guideline for Bioequivalence Studies of Generic Products Index
More informationPharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches.
Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches. Lloyd Stevens PhD Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationEMA/EGA. Session 1: orally administered Modified Release Products European Regulatory Requirements London 30 April 2015 Dr.
EMA/EGA Session 1: orally administered Modified Release Products European Regulatory Requirements London 30 April 2015 Dr. Henrike Potthast Disclaimer The presentation reflects the personal opinion of
More informationMetformin: Mechanistic Absorption Modeling and IVIVC Development
Metformin: Mechanistic Absorption Modeling and IVIVC Development Maziar Kakhi *, Ph.D. FDA Silver Spring, MD 20993 Maziar.kakhi@fda.hhs.gov Viera Lukacova, Ph.D. Simulations Plus Lancaster, CA 93534 viera@simulations-plus.com
More informationPrasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance
31 May 2018 EMA/CHMP/158772/2016/Rev.1 Committee for Medicinal Products for Human Use (CHMP) Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg Draft Agreed by Pharmacokinetics Working Party April
More informationPK-UK Challenges and benefits of using PBPK to evaluate an IVIVC for drugs with nonideal solubility and/or permeability. Bath, November 2014
PK-UK 2014 Challenges and benefits of using PBPK to evaluate an IVIVC for drugs with nonideal solubility and/or permeability Bath, November 2014 Prof. Dr. Jennifer Dressman Dressman Bath 2014 Why IVIVC
More informationExcipient Interactions Relevant For BCS Biowaivers Peter Langguth
Excipient Interactions Relevant For BCS Biowaivers Peter Langguth Department of Pharmaceutical Technology and Biopharmaceutics, Johannes Gutenberg University Mainz, Germany 3rd Symposium on Harmonization
More informationApplication and Experience in the EU of the BCS Concept in the review of new generics & variations
Application and Experience in the EU of the BCS Concept in the review of new generics & variations Dirk M Barends National Institute of Public Health and the Environment The Netherlands APV / IKEV Seminar
More informationModeling and Simulation to Support Development and Approval of Complex Products
Modeling and Simulation to Support Development and Approval of Complex Products Mathangi Gopalakrishnan, MS, PhD Research Assistant Professor Center for Translational Medicine, School of Pharmacy, UMB
More informationAdvantages and Limitations of In Vivo Predictive Dissolution (IPD) Systems
Advantages and Limitations of In Vivo Predictive Dissolution (IPD) Systems November 16 th Prof. Gregory E. Amidon - University of Michigan What is an In vivo Predictive Dissolution (IPD) System? An IPD
More informationDevelopment of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization
Development of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization Nico Holmstock Scientist, Janssen R&D M CERSI 2017, BALTIMORE (USA) Canagliflozin An
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are
More informationVolume 1(3) May-June 2013 Page 351
ISSN: 2321-5674(Print) BIOAVAILABILITY: CRITERIA FOR APPROVING A DRUG PRODUCT FOR MARKETING Sandhya Singh 1, Faheem Ajmal Ansari 1, Shravan Paswan 2*, Rnjan Kumar Sharma 2, Alok Ranjan Gaur 3 1 Azad Institute
More informationUSING PBPK MODELING TO SIMULATE THE DISPOSITION OF CANAGLIFLOZIN
USING PBPK MODELING TO SIMULATE THE DISPOSITION OF CANAGLIFLOZIN Christophe Tistaert PDMS Pharmaceutical Sciences Preformulation & Biopharmaceutics AAPS 2015, FLORIDA (USA) Canagliflozin An orally active
More informationJapanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDevelopment of a New Type of Prolonged Release Hydrocodone Formulation Based on Egalet ADPREM Technology Using In Vivo In Vitro Correlation
Pharmaceutics 211, 3, 73-87; doi:1.339/pharmaceutics3173 Article OPEN ACCESS pharmaceutics ISSN 1999-4923 www.mdpi.com/journal/pharmaceutics Development of a New Type of Prolonged Release Hydrocodone Formulation
More informationAdvantages and Limitations of In Vivo Predictive Dissolution (IPD) Systems
Advantages and Limitations of In Vivo Predictive Dissolution (IPD) Systems November 16 th Prof. Gregory E. Amidon - University of Michigan What is an In vivo Predictive Dissolution (IPD) System? An IPD
More informationBIOEQUIVALENCE AND THERAPEUTIC EQUIVALENCE. Soula Kyriacos, B.Pharm, PhD Head R&D, Pharmaline November 2016
BIOEQUIVALENCE AND THERAPEUTIC EQUIVALENCE Soula Kyriacos, B.Pharm, PhD Head R&D, Pharmaline November 2016 Introduction Early 1970 s FDA regulations for submission of BA data 1984 US Congress passed the
More informationBioequivalence of MR Products. AGAH Conference on the New European Modified Release Guideline Bonn, June 15 th, 2015
Bioequivalence of MR Products AGAH Conference on the New European Modified Release Guideline Bonn, June 15 th, 2015 Disclaimer This presentation represents the personal interpretation and opinion of the
More informationMetformin IR tablets: partial in vitro dissolution profiles differences do not preclude in vivo bioequivalence
Metformin IR tablets: partial in vitro dissolution profiles differences do not preclude in vivo bioequivalence Eva Troja Quality Control Department Profarma SH.A. Pharmaceutical Industry Tirana, Albania
More informationPentoxifylline Extended-Release Tablets 400 mg
Pentoxifylline Extended-Release Tablets 4 mg COMPARATIVE BIOAVAILABILITY STUDIES APOTEX CORP. Product: Pentoxifylline Extended-Release Tablets Approval Date: June 9, 1999 Indication: Description: treatment
More informationDraft Agreed by Pharmacokinetics Working Party February Adoption by CHMP for release for consultation 1 April 2016
15 December 2016 Committee for Medicinal Products for Human Use (CHMP) Everolimus tablets 0.25 mg, 0.5 mg, 0.75 mg and 1 mg; 2.5 mg, 5 mg and 10 mg, dispersible tablets 0.1 mg and 0.25 mg; 2 mg, 3 mg and
More informationCurrent Challenges and Opportunities in Demonstrating Bioequivalence
Current Challenges and Opportunities in Demonstrating Bioequivalence Gur Jai Pal Singh, Ph.D. Watson Laboratories, Inc. Corona, California, USA Demonstrating Bioequivalence of Locally Acting Orally Inhaled
More informationOral Soluble Film Products for Epilepsy: Clobazam (COSF) and Diazepam (DBSF)
Oral Soluble Film Products for Epilepsy: Clobazam (COSF) and Diazepam (DBSF) Michael A. Rogawski, M.D., Ph.D. Professor of Neurology and Pharmacology School of Medicine University of California, Davis
More informationSCIENTIFIC DISCUSSION. Antimycobacterial (J04AC01).
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): International Nonproprietary Name: Pharmaco-therapeutic
More informationAbsolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches.
Absolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches. Dr Lloyd Stevens Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationPrequalification Programme Bioequivalence Assessment Update. Dr. John Gordon
Prequalification Programme Bioequivalence Assessment Update Dr. John Gordon WHO Prequalification of Medicines Programme 3 rd Meeting with Manufacturers of FPPs and APIs Overview Review of commonly used
More informationPublic Assessment Report. Scientific discussion. Metoprololsuccinat Actavis. Prolonged release tablets 25 mg, 50 mg, 100 mg and 200 mg
Public Assessment Report Scientific discussion Metoprololsuccinat Actavis Prolonged release tablets 25 mg, 50 mg, 100 mg and 200 mg Metoprolol succinate This module reflects the scientific discussion for
More informationClinical Trials A Practical Guide to Design, Analysis, and Reporting
Clinical Trials A Practical Guide to Design, Analysis, and Reporting Duolao Wang, PhD Ameet Bakhai, MBBS, MRCP Statistician Cardiologist Clinical Trials A Practical Guide to Design, Analysis, and Reporting
More informationDr. M.Mothilal Assistant professor
Dr. M.Mothilal Assistant professor Bioavailability is a measurement of the rate and extent of drug that reaches the systemic circulation from a drug product or a dosage form. There are two different types
More informationPQRI Workshop Bethesda 2012
Review of GI physiology and use of biorelevant media PQRI Workshop Bethesda 2012 Prof. Dr. Jennifer Dressman An IVIVC can only be as good as the data used to produce it! With respect to the dissolution
More informationIPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M.
IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Case Study: Pharmacokinetics and Pharmacodynamics of Tiotropium and Salmeterol Following Parallel Administration in COPD Patients Using Different
More informationDEVELOPMENT OF IN VITRO-IN VIVO CORRELATION FOR ENCAPSULATED METOPROLOL TARTRATE
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 70 No. 4 pp. 743ñ747, 2013 ISSN 0001-6837 Polish Pharmaceutical Society DEVELOPMENT OF IN VITRO-IN VIVO CORRELATION FOR ENCAPSULATED METOPROLOL TARTRATE
More informationEffect of Excipients on Dissolution: Case Studies with Bio-relevant/ Hydro-alcoholic Media
Effect of Excipients on Dissolution: Case Studies with Bio-relevant/ Hydro-alcoholic Media Sandip B. Tiwari, Ph.D. Technical Director: South Asia Colorcon Asia Pvt. Ltd., Goa, India DISSO-INDIA 2013, May
More informationBIOAVAILABILITY OF CIPROFLOXACIN TABLETS IN HUMANS AND ITS CORRELATION WITH THE DISSOLUTION RATES
BIOAVAILABILITY OF CIPROFLOXACIN TABLETS IN HUMANS AND ITS CORRELATION WITH THE DISSOLUTION RATES MUHAMMAD KHALID KHAN*, MUHAMMAD FARID KHAN, HAROON KHAN AND G. MUSTAFA Faculty of Pharmacy, Gomal University,
More informationAltered GI absorption in special populations: An industry perspective
Altered GI absorption in special populations: An industry perspective Cordula Stillhart and Neil J. Parrott F. Hoffmann La Roche Ltd, Basel (CH) UNGAP WG meeting, Leuven (B) 8 March 2018 Current challenges
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationRationale for dissolution testing. Dissolution testing of nonconventional. Dissolution for IVIVC. Practicality of testing. Apparatus 3 BP 2011
Rationale for dissolution testing Dissolution testing of nonconventional dosage forms Prof Barbara Conway Annual Symposium for Technical Services 27 th Sept 211 Purpose of dissolution test Product development
More informationUSE OF BIO-PREDICTIVE METHODS DURING EARLY FORMULATION SCREENING
USE OF BIO-PREDICTIVE METHODS DURING EARLY FORMULATION SCREENING Jesse L. Kuiper, Ph.D. (Merck) Carrie A. Coutant, Ph.D. (Eli Lilly) Merck Research Laboratories 15-May-2017 1 Acknowledgements 1X Dissolution
More informationHydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems D. Tewari, R. K. Lewis, W. W. Harcum and T Dürig
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-069-1 (Supersedes PTR-069) Page 1 of 8 Hydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems
More informationHelmut Schütz. The Global Bioequivalence Harmonisation Initiative. 12 April 2018 [Session II: Necessity of multiple dose studies in BE testing] 1
Primary and secondary PK metrics for evaluation of steady state studies, C min vs.c τ, relevance of C min /C τ or fluctuation for bioequivalence assessment Helmut Schütz 12 April 2018 [Session II: Necessity
More informationClinical Endpoint Bioequivalence Study Review in ANDA Submissions. Ying Fan, Ph.D.
Clinical Endpoint Bioequivalence Study Review in ANDA Submissions Ying Fan, Ph.D. 1 Disclaimer This presentation constitutes an informal communication that represents the best judgment of the speaker at
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationBiopharmaceutics of Non-Orally Administrated Drugs
Biopharmaceutics of Non-Orally Administrated Drugs Robert Lionberger, Ph.D. Deputy Director for Science (acting) Office of Generic Drugs, FDA November 21, 2013 AAPS Webinar Opinions expressed in this presentation
More informationMETHODS OF STUDYING BIOAVAILABILITY AND BIOEQUIVALENCE
METHODS OF STUDYING BIOAVAILABILITY AND BIOEQUIVALENCE INTRODUCTION: A multisource drug product is a drug product that contains the same active drug substance in the same dosage form and is marketed by
More informationPHARMACEUTICAL TECHNOLOGY REPORT. Abstract Summary. Introduction. Experimental Methods. Consumer Specialties ashland.com
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-037-3 (Supersedes PTR-037-2) Page 1 of 7 Hydrodynamic Robustness of Hypromellose and Hydroxypropyl Cellulose Based Modified Release
More informationDRAFT GUIDANCE DOCUMENT Comparative Bioavailability Standards: Formulations Used for Systemic Effects
1 2 3 DRAFT GUIDANCE DOCUMENT Comparative Bioavailability Standards: Formulations Used for Systemic Effects 4 This guidance document is being distributed for comment purposes only. 5 6 Published by authority
More informationSCIENTIFIC DISCUSSION. Efavirenz
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredient (API): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
25 January 2018 EMA/CHMP/729976/2017 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Paracetamol oral use, immediate release formulations product-specific bioequivalence
More informationFolic Acid in Human Nutrition
Folic Acid in Human Nutrition Folic acid is a water soluble B vitamin widely distributed in foods. Deficiencies lead to impaired cell division and altered protein synthesis. Newborn children of women receiving
More informationSoma)con PHARMACEUTICALS
Soma)con PHARMACEUTICALS 5357 11 OCT 20 A10 AO Division of Dockets Management (HFA-305) Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852
More informationJack Cook, PhD & Vivek Purohit, PhD Clinical Pharmacology Pfizer, Inc.
Challenges and Strategies to Facilitate Formulation Development of Pediatric Drug Products Biopharmaceutical Considerations in Pediatric Formulation Development Jack Cook, PhD & Vivek Purohit, PhD Clinical
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are
More informationBioequivalence Requirements: USA and EU
Bioequivalence Requirements: USA and EU Dr. Nicholas Cappuccino Chair, IGPA Science Committee Global Head of Quality, Dr. Reddy s Laboratories Ltd. 15 th Annual IGPA Conference Kyoto, Japan December 6,
More informationSCIENTIFIC DISCUSSION. AkuriT-3 Tablets*
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More informationTablet Dissolution Testing
31-Jan-11 Tablet Dissolution Testing Official Requirements and Solutions offered by Tablet Dissolution Testing Contents Contents General Requirements Qualification guidelines Dissolution Automation New
More informationFORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS
International Journal of PharmTech Research CODEN( USA): IJPRIF ISSN : 0974-4304 Vol.1, No.3, pp 634-638, July-Sept 2009 FORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS K. Reeta Vijaya
More informationImpact of Sample Preparation on Dissolution Testing: Drug Binding and Extractable Impurities and Their Effect on Dissolution Data
dx.doi.org/10.14227/dt150408p20 Impact of Sample Preparation on Dissolution Testing: Drug Binding and Extractable Impurities and Their Effect on Dissolution Data e-mail: vivek_joshi@millipore.com Vivek
More informationThe Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.
Nitrofurantoin Capsules Type of Posting Revision Bulletin Posting Date 28 Dec 2018 Official Date 01 Jan 2019 Expert Committee Chemical Medicines Monographs 1 Reason for Revision Compliance In accordance
More informationPublic Assessment Report. Scientific discussion. Leflunomide Apotex 10 mg and 20 mg, tablets. (leflunomide) NL/H/2548/ /DC
Public Assessment Report Scientific discussion Leflunomide Apotex 10 mg and 20 mg, tablets (leflunomide) 001-002/DC Date: 3 August 2015 This module reflects the scientific discussion for the approval of
More informationFinal Report (Amendment 1) April 11, 2006 Page 4 of 50
Page 4 of 50 2 SYNOPSIS Title: A Bioavailability Study to Assess the Bioequivalence of Alfacalcidol Capsule and Oral Drop Formulations: A Comparative, Randomized, Single-Dose, 4-Way Crossover Bioavailability
More informationQuality Attribute Considerations for Chewable Tablets Guidance for Industry
Quality Attribute Considerations for Chewable Tablets Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationThe Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation
METHOCEL Premium Cellulose Ethers Application Data The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation INTRODUCTION Hydrophilic matrices
More informationPHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-8 Page 1 of 6 Are Cellulosic Controlled Release Technologies Vulnerable to Dose Dumping in Ethanolic Dissolution Media? Elanor Pinto,
More informationBiopharmaceutics Lecture-11 & 12. Pharmacokinetics of oral absorption
Biopharmaceutics Lecture-11 & 12 Pharmacokinetics of oral absorption The systemic drug absorption from the gastrointestinal (GI) tract or from any other extravascular site is dependent on 1. 2. 3. In the
More informationTransdermal Delivery of Newer Atypical Antipsychotics ABSTRACT
Transdermal Delivery of Newer Atypical Antipsychotics ABSTRACT Abstract Risperidone and olanzapine, newer atypical antipsychotics are highly effective and safer in the treatment of psychosis. A low dose
More informationFed and Fasted Conditions Dissolution Studies
Fed and Fasted Conditions Dissolution Studies Prof. Dr. Nevin ÇELEBİ Gazi University Faculty of Pharmacy Department of Pharmaceutical Technology-Ankara/TURKEY E-mail:ncelebi@gazi.edu.tr Int.Symp.Dissolution
More informationBiowaiver for Immediate Release Solid Oral Dosage Form: A General Overview
Human Journals Review Article August 2018 Vol.:13, Issue:1 All rights are reserved by Tekendra Pant et al. Biowaiver for Immediate Release Solid Oral Dosage Form: A General Overview Keywords: Biowaiver,
More informationPREDICTING DRUG INTERACTIONS FROM DISSOLUTION STUDIES. Imre Klebovich
PREDICTING DRUG INTERACTIONS FROM DISSOLUTION STUDIES Imre Klebovich Semmelweis University Department of Pharmaceutics Disso India Goa 2015 International Annual Symposium on Dissolution Science 31 st August
More informationThis revision also necessitates a change in the table numbering in the test for Organic Impurities.
Methylphenidate Hydrochloride Extended-Release Tablets Type of Posting Notice of Intent to Revise Posting Date 27 Jul 2018 Targeted Official Date To Be Determined, Revision Bulletin Expert Committee Chemical
More informationPublic Assessment Report. Scientific discussion. Carvedilol Aurobindo 6.25 mg and 25 mg, film-coated tablets (carvedilol) NL/H/2609/ /MR
Public Assessment Report Scientific discussion Carvedilol Aurobindo 6.25 mg and 25 mg, film-coated tablets (carvedilol) NL/H/2609/001-002/MR Date: 26 May 2014 This module reflects the scientific discussion
More informationSCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationSTUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS
Int. J. Chem. Sci.: 10(4), 2012, 1934-1942 ISSN 0972-768X www.sadgurupublications.com STUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS K. VENUGOPAL * and K. P. R. CHOWDARY a Nirmala College
More informationPublic Assessment Report Scientific discussion. Ivabradine Grindeks 5 mg and 7.5 mg and filmcoated. Ivabradine hydrochloride ES/H/0375/ /DC
Public Assessment Report Scientific discussion Ivabradine Grindeks 5 mg and 7.5 mg and filmcoated tablets Ivabradine hydrochloride ES/H/0375/001-002/DC Registration number in Spain: 81.898, 81.899 This
More informationPHARMACOKINETICS OF DRUG ABSORPTION
Print Close Window Note: Large images and tables on this page may necessitate printing in landscape mode. Applied Biopharmaceutics & Pharmacokinetics > Chapter 7. Pharmacokinetics of Oral Absorption >
More informationCompliance. Should you have any questions, please contact Behnaz Almasi, Associate Scientific Liaison ( or
Extended-Release Tablets Type of Posting Revision Bulletin Posting Date 30 Mar 2018 Official Date 01 Apr 2018 Expert Committee Chemical Medicines Monographs 3 Reason for Revision Compliance In accordance
More informationDecentralised Procedure. Public Assessment Report. Zolmitriptan Renantos 2.5 mg Orodispersible film 5 mg Orodispersible film DE/H/2295/ /DC
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Zolmitriptan Renantos 2.5 mg Orodispersible film 5 mg Orodispersible film DE/H/2295/001-002/DC Applicant:
More informationTEPZZ A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A61K 9/00 ( ) A61K 9/20 (2006.
(19) TEPZZ 96746A_T (11) EP 2 96 746 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 13.01.16 Bulletin 16/02 (1) Int Cl.: A61K 9/00 (06.01) A61K 9/ (06.01) (21) Application number: 102377.1
More informationHelmut Schütz. BioBriges 2018 Prague, September
Multi-Group Studies in BE. Multi-Group Studies in Bioequivalence. To pool or not to pool? Helmut Schütz BioBriges 2018 Prague, 26 27 September 2018 1 Remember Whenever a theory appears to you as the only
More informationQ&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution)
Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution) This document should not be treated as a comprehensive guideline; it serves as a
More informationSCIENTIFIC DISCUSSION. Lopinavir and Ritonavir 200 mg/50 mg Tablets * Name of the Finished Pharmaceutical Product:
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More informationPublic Assessment Report Scientific discussion. Risperidon Mylan film-coated tablets (Risperidone) SE/H/712/01-07/MR
Public Assessment Report Scientific discussion Risperidon Mylan film-coated tablets (Risperidone) SE/H/712/01-07/MR This module reflects the scientific discussion for the approval of Risperidon Mylan.
More informationModified Release: C min C τ. Modified Release
Wikimedia Commons 2007 Sokoljan Creative Commons Attribution-ShareAlike 3.0 Unported Modified Release: C min C τ Modified Release C C min C τ Helmut Schütz BEBAC 1 24 Another Reminder Rose is a rose is
More informationWHOPAR. SCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationSCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary, which are included in parts
More informationBioequivalence of Inhaled Corticosteroids. -with emphasis on Pharmacokinetic Tools.
Bioequivalence of Inhaled Corticosteroids -with emphasis on Pharmacokinetic Tools? hochhaus@ufl.edu Topics related to Bioequivalence 10-60 % Deposited in lung Complete absorption from the lung Cl muc Mouth
More informationDecentralised Procedure. Public Assessment Report
Decentralised Procedure Public Assessment Report Venlafaxin ratiopharm Venlafaxin AbZ-Pharma Venlafaxin CT-Arzneimittel prolonged-release capsule hard venlafaxine hydrochloride DE/H/3393-3395/01-03/DC
More informationA Review Article on Bioavailability and Bioequivalence Studies
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.5, No.4, pp 1711-1721, Oct-Dec 2013 A Review Article on Bioavailability and Bioequivalence Studies Srivastav Atul Kumar*,
More information